| Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 | Mar'18 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-4,852 | 744 | -9,087 | 3,104 | -5,460 | -965 | |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||
Depreciation and amortization expense | ||||||
3,922 | 3,795 | 3,696 | 3,726 | 3,484 | 3,584 | |
Provision for bad debts and product returns | ||||||
151 | 666 | 233 | 351 | 345 | 149 | |
Provision for inventory write-downs | ||||||
2,208 | 1,744 | 1,530 | 2,041 | 8,224 | 2,641 | |
Amortization of deferred revenue | ||||||
1,187 | 1,293 | 1,292 | 1,217 | 1,218 | 1,217 | |
Deferred income tax benefit | ||||||
-1,526 | -3,173 | 470 | 1,457 | -2,633 | -38 | |
Stock-based compensation | ||||||
969 | 1,267 | 1,163 | 1,080 | 1,290 | 1,280 | |
Other | ||||||
-192 | -680 | -197 | -118 | -201 | -409 | |
Change in assets and liabilities: | ||||||
Accounts receivable | ||||||
769 | 1,087 | 2,422 | -1,053 | 4,528 | 3,112 | |
Inventories | ||||||
3,826 | -1,664 | 2,742 | 5,432 | 2,538 | -2,127 | |
Accounts payable | ||||||
-2,933 | -2,422 | -7,253 | 4,629 | -290 | -3,513 | |
Accrued expenses | ||||||
6,546 | -632 | -1,585 | -1,825 | 1,285 | -3,877 | |
Deferred revenue | ||||||
0 | -4,000 | 2,000 | 0 | -4,000 | 2,000 | |
Other operating assets and liabilities | ||||||
-32 | -738 | 593 | 4,560 | -8,021 | 917 | |
Net cash (used in) provided by operating activities | ||||||
402 | 2,574 | -15,685 | 1,629 | 10,827 | -1,449 | |
Cash flows from investing activities: | ||||||
Purchases of property, plant and equipment | ||||||
3,970 | 3,435 | 3,477 | 3,250 | 1,738 | 2,118 | |
Patent and acquired intangible asset costs | ||||||
660 | 798 | 328 | 2,070 | 398 | 330 | |
Net cash used in investing activities | ||||||
-4,401 | -4,233 | -103,726 | -2,320 | -2,136 | -23,448 | |
Cash flows from financing activities: | ||||||
Proceeds from exercise of common stock options | ||||||
0 | 111 | 284 | 905 | 35 | 1,394 | |
Proceeds from long-term obligations | ||||||
3,000 | 0 | 115,000 | 0 | 54,425 | 20,000 | |
Payments of debt issuance costs | ||||||
0 | 0 | 729 | - | - | - | |
Payments on long-term obligations | ||||||
- | - | - | 4,421 | 61,625 | 5,125 | |
Net cash provided by financing activities | ||||||
2,500 | 111 | 114,555 | -3,525 | -8,191 | 16,269 | |
Effect of exchange rate changes on cash and cash equivalents | ||||||
-69 | 23 | -50 | -8 | -66 | 59 | |
Net decrease in cash and cash equivalents | ||||||
- | -1,525 | -4,906 | - | 434 | -8,569 | |
Supplemental cash flow disclosure: | ||||||
Cash paid for interest | ||||||
2,209 | 2,175 | 557 | 543 | 1,374 | 600 | |
Income tax refunds, net of payments | ||||||
0 | 2,617 | -635 | - | - | - | |
Non-cash acquisition of property, plant and equipment | ||||||
361 | -46 | 502 | -205 | 519 | 157 | |
Increase in accrual for dividend payable | ||||||
- | - | - | 173 | 981 | 966 | |
Non-cash common stock issuance | ||||||
0 | 0 | 60,730 | - | - | - | |
Zyga Technology Inc [Member] | ||||||
Payments to acquire businesses | ||||||
- | - | - | 0 | 0 | 21,000 | |
Paradigm Spine [Member] | ||||||
Payments to acquire businesses | ||||||
-229 | 0 | 99,921 | - | - | - | |
Non-cash acquisition of Paradigm Spine | ||||||
0 | 0 | 60,730 | - | - | - | |